CNX Therapeutics appoints Peter Butterfield as Chief Operating Officer

London, February 25 2025 - CNX Therapeutics Limited (“CNX Therapeutics”) today announced the appointment of Peter Butterfield as Chief Operating Officer, effective February 19, 2025. Peter brings extensive pharmaceutical and consumer healthcare experience to CNX Therapeutics, having most recently served as Chief Executive Officer of Alliance Pharmaceuticals.

Peter joined the Board of Alliance Pharmaceuticals in 2010 and was appointed CEO in 2018, where he grew the business through both organic initiatives and strategic M&A. With over 14 years at Alliance, including six as CEO, Peter has a proven track record of delivering shareholder value, building high-performing teams and scaling businesses across diverse therapy areas and geographies.

"I am delighted to join CNX Therapeutics at such an exciting time in the company's development," said Peter Butterfield. "CNX has established itself as an innovative player in the industry and I look forward to working with the team to drive our next phase of growth while maintaining the strong values-based culture that has been critical to the company's success."

Guy Clark, CEO of CNX Therapeutics, commented: "We are excited to welcome Peter to the CNX team. His extensive expertise in the pharmaceutical sector and proven leadership in scaling businesses will be invaluable as we continue to grow and innovate. Peter’s arrival marks an important step forward in our strategic journey.”

Before his time at Alliance Pharmaceuticals, Peter held senior positions across the pharmaceutical and consumer healthcare sectors in both public and private companies.

CNX Therapeutics was acquired by Inflexion Private Equity, a leading mid-market private equity firm, in 2021.